Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels

Size: px
Start display at page:

Download "Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels"

Transcription

1 Online supplement to: Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels Supplementary Figure 1. CONSORT disposition of study patients. Supplementary Figure 2. Per-protocol proportion of patients with HBV DNA <69 IU/mL throughout the study. Supplementary Figure 3. Week 192 viral loads of those subjects with detectable HBV DNA at the end of the study. Supplementary Figure 4. Proportion of patients receiving TDF alone (solid circle) or TDF/FTC (open circle) who achieve a >0.5 log10 HBsAg decline from baseline. Proportion is based on subjects with values at each time point (on-treatment). Supplementary Figure 5. Mean values of HBsAg over time among patients receiving TDF alone (solid circle) or TDF/FTC (open circle). Supplementary Table 1. ITT analysis of achieving the primary efficacy endpoint for patients who achieve and don t achieve the primary endpoint at Week 48. Supplementary Table 2. Per-protocol analysis of achieving the primary efficacy endpoint for patients who achieve and don t achieve the primary endpoint at Week 48. Supplementary Table 3. HBV DNA levels of patients with HBV DNA >69 IU/mL at Week 192 over the final year of treatment. Supplementary Table 4. Bivariate analysis of associations of baseline characteristics with having HBV DNA <29 IU/mL among those subjects with Week 192 values. Supplementary Table 5. Odds ratio of baseline characteristics from logistic regression analysis of those subjects with Week 192 values. Supplementary Table 6. Cox proportional hazard analysis evaluating predictors of achieving either HBV DNA <69 IU/mL or HBV DNA <29 IU/mL. Supplementary Table 7. Intention to treat and per protocol proportion of patients with HBV DNA <69 IU/mL at Week 192 by baseline HBV DNA level. Supplementary Table 8. Resistance Surveillance of HBV isolates. Supplementary Table 9. Phosphate, egfr (calculated using Cockcroft-Gault) over time.

2 Supplementary Figure 1: CONSORT disposition of study patients. 309 Assessed for eligibility 180 Excluded (Screening Failures) 129 Randomized 64 Allocation to TDF/FTC 62 Received TDF/FTC 2 Did not receive TDF/FTC 65 Allocation to TDF 64 Received TDF 1 Did not receive TDF 1 Lost to follow-up 9 (15%) Discontinued TDF/FTC 1 Investigator s decision 1 Protocol violation 5 Withdrawal of consent 2 Adverse events * 0 Lost to follow-up 12 (18%) Discontinued TDF 2 Investigator s decision 1 Protocol violation 8 Withdrawal of consent 1 Adverse events ** 54 (87%) remaining in study at Week (83%) remaining in study at Week 192 * depression, spontaneous abortion ** death (homicide)

3 Supplemental Figure 2: Per-protocol proportion of patients with HBV DNA <69 IU/mL throughout the study.

4 Supplemental Figure 3: Week 192 viral loads of those subjects with detectable HBV DNA at the end of the study.

5 M e a n H B s A g (lo g 1 0 IU /m L ) Supplemental Figure 4: Proportion of patients receiving TDF alone (solid circle) or TDF/FTC (open circle) who achieve a >0.5 log 10 HBsAg decline from baseline. Proportion is based on subjects with values at each time point (on-treatment). Supplemental Figure 5: Mean values of HBsAg over time among patients receiving TDF alone (solid circle) or TDF/FTC (open circle) T D F T D F /F T C W e e k o f S tu d y

6 Supplemental Table 1: ITT analysis of achieving the primary efficacy endpoint for patients who achieve and don t achieve the primary endpoint at Week 48. TDF FTC+TDF HBV DNA >69 IU/mL at Week 48, N HBV DNA <69 IU/mL at Week 96, n/n (%) 12/36 (33.3%) 14/21 (66.7%) HBV DNA <69 IU/mL at Week 144, n/n (%) 20/36 (55.6%) 17/21 (81.0%) HBV DNA <69 IU/mL at Week 192, n/n (%) 16/36 (44.4%) 14/21 (66.7%) HBV DNA 69 IU/mL at Week 48, N DNA<400 copies/ml at Week 96, n/n (%) 22/26 (84.6%) 33/37 (89.2%) DNA<400 copies/ml at Week 144, n/n (%) 20/26 (76.9%) 33/37 (89.2%) DNA<400 copies/ml at Week 192, n/n (%) 19/26 (73.1%) 33/37 (89.2%) Supplemental Table 2: Per-protocol analysis of achieving the primary efficacy endpoint for patients who achieve and don t achieve the primary endpoint at Week 48. TDF FTC+TDF HBV DNA >69 IU/mL at Week 48 HBV DNA <69 IU/mL at Week 96, n/n (%) 12/36 (33.3%) 14/21 (66.7%) HBV DNA <69 IU/mL at Week 144, n/n (%) 20/33 (60.6%) 17/21 (81.0%) HBV DNA <69 IU/mL at Week 192, n/n (%) 16/33 (48.5%) 14/20 (70.0%) HBV DNA 69 IU/mL at Week 48 DNA<400 copies/ml at Week 96, n/n (%) 22/23 (95.7%) 33/35 (94.3%) DNA<400 copies/ml at Week 144, n/n (%) 20/22 (90.9%) 33/35 (94.3%) DNA<400 copies/ml at Week 192, n/n (%) 19/20 (95.0%) 33/34 (97.1%)

7 Supplemental Table 3: HBV DNA levels of patients with HBV DNA >69 IU/mL at Week 192 over the final year of treatment. Subject Number Treatment Arm HBV DNA (IU/mL) Week 144 Week 160 Week 176 Week TDF TDF <29 46 < TDF 41 < TDF TDF TDF TDF TDF TDF <29 <29 < TDF TDF TDF TDF TDF < TDF TDF TDF TDF TDF+FTC 37 < TDF+FTC <29 < TDF+FTC TDF+FTC <29 <29 < TDF+FTC <29 <29 < TDF+FTC TDF+FTC <29 <29 <

8 Supplemental Table 4: Bivariate analysis of associations of baseline characteristics with having HBV DNA <29 IU/mL among those subjects with Week 192 values. HBV DNA 29 IU/mL N=35 HBV DNA <29 IU/mL N=72 p- value Female gender, n/n (%) 11/35 (31.4) 40/72 (55.6) Baseline HBsAg, log 10, mean TDF/FTC treatment, n/n (%) 11/35 (31.4) 43/72 (59.7) Baseline HBV DNA, log 10, mean Age >30, n/n (%) 18/35 (51.4) 41/72 (56.9) 0.68 Genotype B, n/n (%) 19/35 (54.3) 32/72 (44.4) Asian race, n/n (%) 29/35 (82.9) 66/72 (91.7) Baseline BMI, n/n (%) Baseline ALT, n/n (%) Years of HBV Positive, n/n (%) Age, n/n (%) Supplemental Table 5: Odds ratio of baseline characteristics from logistic regression analysis of those subjects with Week 192 values. Odds Ratio Confidence Interval Female gender TDF/FTC treatment Supplemental Table 6: Cox proportional hazard analysis evaluating predictors of achieving either HBV DNA <69 IU/mL or HBV DNA <29 IU/mL. Hazard Ratio Confidence Interval HBV DNA <69 IU/mL at Wk 192 Female gender TDF/FTC treatment Baseline HBsAg HBV DNA <29 IU/mL at Wk Female gender TDF/FTC treatment Baseline HBsAg

9 Supplemental Table 7: Intention to treat and per protocol proportion of patients with HBV DNA <69 IU/mL at Week 192 by baseline HBV DNA level. TDF 300mg + placebo TDF 300mg + FTC 200mg Intention To Treat, % (CI) HBV DNA <9 log10 copies/ml 57.1 ( ) 84.2 ( ) HBV DNA 9 log10 copies /ml 53.5 ( ) 72.1 ( ) Per Protocol, n/n (%) HBV DNA <9 log10 copies /ml 75 ( ) 88.9 ( ) HBV DNA 9 log10 copies /ml 62.2 ( ) 86.1 ( ) Supplemental Table 8: Resistance Surveillance of HBV isolates. TDF 300mg + placebo (n=64) TDF 300mg + FTC 200mg (n=62) HBV Genotype performed Baseline, n (%) 63 (98) 62 (100) Week 48, n (%) 36 (56) 24 (39) Week 96, n (%) 26 (41) 10 (16) Week 144, n (%) 16 (25) 7 (11) Week 192, n (%) 18 (28) 8 (13) HBV genotype samples, total samples/unique subjects 96/40 49/29 Unable to PCR No changes from baseline pol/rt Conserved-site changes 6 5 rtl29f/l 2 0 rtp170p/s 0 2 Unique polymorphic-site changes 16 9

10 Supplemental Table 9: Phosphate, egfr (calculated using Cockcroft-Gault) over time. TDF 300mg + placebo (n=64) TDF 300mg + FTC 200mg (n=62) Phosphate mg/dl (median) Baseline Wk Wk Wk Wk egfr ml/min (median) Baseline Wk Wk Wk Wk GFR <70 ml/min, n (%) 0 5 (8.1) GFR <60 ml/min, n (%) 0 2 (3.2) GFR decline by 20%, n (%) 10 (15.6) 14 (22.6)

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Tenofovir as a drug of choice for the chronic hepatitis B treatment

Tenofovir as a drug of choice for the chronic hepatitis B treatment EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis

More information

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Gilead Sciences, Durham, NC, USA

Gilead Sciences, Durham, NC, USA Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF () for Treatment of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil: Final Week 168

More information

Management of Decompensated Chronic Hepatitis B

Management of Decompensated Chronic Hepatitis B Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Bristol-Myers Squibb

Bristol-Myers Squibb A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:

More information

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,

More information

Clinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

Clinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Clinical Case Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Paris, January 16th 2018 Links of interest and Disclaimer Adviser, speaker, investigator for: Abbvie, BMS,

More information

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Does Viral Cure Prevent HCC Development

Does Viral Cure Prevent HCC Development Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,

More information

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110 BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:

More information

Don t interfere My first choice is always nucs!

Don t interfere My first choice is always nucs! Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr

More information

NUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.

NUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from

More information

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,

More information

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled

More information

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse. Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,

More information

Is there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain

Is there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal

More information

Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne

Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues

More information

Management of HBV infection between Specialist and General Practitioners

Management of HBV infection between Specialist and General Practitioners 13 October 2016 Management of HBV infection between Specialist and General Practitioners Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico

More information

Tenofovir Alafenamide (TAF)

Tenofovir Alafenamide (TAF) Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016

More information

Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta

Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis

More information

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)

More information

SYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase

SYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical

More information

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects

More information

Current Status of HBV and Liver Transplant

Current Status of HBV and Liver Transplant Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing

More information

Per the study design and a limitation of this analysis, swabs were not tested for HPV types 6

Per the study design and a limitation of this analysis, swabs were not tested for HPV types 6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 SUPPLEMENTARY MATERIAL Progression, regression, and clearance of HPV6/11 infections Per the study design and a limitation of this analysis, swabs

More information

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping

More information

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated

More information

Antiretroviral Treatment Strategies: Clinical Case Presentation

Antiretroviral Treatment Strategies: Clinical Case Presentation Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.

More information

Inarigivir: A novel RIG-I agonist for chronic hepatitis B

Inarigivir: A novel RIG-I agonist for chronic hepatitis B : A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,

More information

ART Treatment. ART Treatment

ART Treatment. ART Treatment Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r

More information

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has

More information

For now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit

For now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS

More information

Arbutus Biopharma Corporation, Burnaby, Canada.

Arbutus Biopharma Corporation, Burnaby, Canada. HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in Positive and Negative Virally Suppressed Patients With Hepatitis B Kosh Agarwal 1, Ed Gane 2, Wendy Cheng

More information

How to use pegylated Interferon for Chronic Hepatitis B in 2015

How to use pegylated Interferon for Chronic Hepatitis B in 2015 How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE

More information

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK;

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK; Switching from Kivexa [KVX] (ABC/3TC) + Efavirenz [EFV] to [ATR] (EFV/FTC/TDF) Reduces Cholesterol in Hypercholesterolaemic Subjects: Primary Endpoint Results of a 24- Week Randomised Study C Orkin, 1

More information

Hepatitis B Case Studies

Hepatitis B Case Studies NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No

More information

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral

More information

The results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain

The results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable

More information

Hepatitis B: Future treatment developments

Hepatitis B: Future treatment developments Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main

More information

Background. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)

Background. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012) Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)

More information

HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But

HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,

More information

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular

More information

Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection

Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?

More information

Treatment of hepatitis B : the guidelines and real life

Treatment of hepatitis B : the guidelines and real life Treatment of hepatitis B : the guidelines and real life Prince of Songkla University, Thailand Teerha Piratvisuth MD. NKC Institute of Gastroenterology and Hepatology Disclosure Statement of Financial

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd

tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015 THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

HBV Therapy in Special Populations: Liver Cirrhosis

HBV Therapy in Special Populations: Liver Cirrhosis HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

MF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9

MF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9 SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab

More information

Statistical Analysis Plan (SAP)

Statistical Analysis Plan (SAP) Statistical Analysis Plan (SAP) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax in Ethiopia: a randomized controlled trial Contents

More information

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,

More information

HBV Diagnosis and Treatment

HBV Diagnosis and Treatment HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA

More information

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History

More information

Guidelines for PrEP in PWID

Guidelines for PrEP in PWID Guidelines for PrEP in PWID Any use of injection drugs (past 6 months) AND Any sharing of injection equipment OR participation in methadone, naloxone, or buprenorphine treatment program (past 6 months)

More information

TDF Renal Dysfunction

TDF Renal Dysfunction TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape

More information

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

More information

Vemlidy. (tenofovir alafenamide) New Product Slideshow

Vemlidy. (tenofovir alafenamide) New Product Slideshow Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength

More information

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

Update on HBV Treatment

Update on HBV Treatment Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,

More information

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Dig Dis Sci (2015) 60:1457 1464 DOI 10.1007/s10620-014-3486-7 ORIGINAL ARTICLE Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Maria

More information

Faculty: Relationships with financial sponsors: Speakers Bureau/Honoraria: Advisory board/consulting Fees:

Faculty: Relationships with financial sponsors: Speakers Bureau/Honoraria: Advisory board/consulting Fees: Faculty/Presenter Disclosure Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead, ViiV, Merck. Advisory board/consulting Fees: Gilead, ViiV, Merck. Dr Joss de

More information

Chemotherapy-induced HBV reactivation in cancer patients

Chemotherapy-induced HBV reactivation in cancer patients Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares

More information

Introduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.

Introduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2. Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in

More information

ART=antiretroviral therapy; C=cobicistat; D=darunavir; F=emtricitabine; STR=single-tablet regimen; TAF=tenofovir alafenamide.

ART=antiretroviral therapy; C=cobicistat; D=darunavir; F=emtricitabine; STR=single-tablet regimen; TAF=tenofovir alafenamide. AMBER A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients Eron JJ, Orkin C, Gallant J, Molina J-M, Negredo E, Antinori A, Mills

More information

COMPETING INTEREST OF FINANCIAL VALUE

COMPETING INTEREST OF FINANCIAL VALUE BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams

More information

coinfected patients predicts HBsAg clearance during long term exposure to tenofovir

coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia

More information

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

Treatment of chronic hepatitis B 2013 update

Treatment of chronic hepatitis B 2013 update 22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical

More information

The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors

The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors Aura Temereanca 1,2, Luminita Ene 3, Adelina Rosca

More information

Is there a need for combination treatment? Yes!

Is there a need for combination treatment? Yes! 18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University

More information

HBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?

HBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue? 4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal

More information

Presentation #: OP221

Presentation #: OP221 Pharmacokinetics, Safety and Tolerability of, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects Presentation #: OP22 Tawesak Tanwandee,

More information

Nuevos tratamientos para la hepatitis B y Delta.

Nuevos tratamientos para la hepatitis B y Delta. Nuevos tratamientos para la hepatitis B y Delta. Dra. María Buti. Servicio de Hepatología. Hospital Universitario Vall d Hebron. Barcelona. hat does HBV cure mean? Functional Cure Clinical resolution sustained

More information

CROI 2013: New Drugs for Treatment and PrEP

CROI 2013: New Drugs for Treatment and PrEP NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment

More information

ASSESSMENT REPORT FOR HEPSERA. International Nonproprietary Name: Adefovir Dipivoxil. Procedure No. EMEA/H/C/485/II/30

ASSESSMENT REPORT FOR HEPSERA. International Nonproprietary Name: Adefovir Dipivoxil. Procedure No. EMEA/H/C/485/II/30 London, 4 January 8 Product Name: Hepsera Procedure Number: EMEA/H/C/485/II/3 ASSESSMENT REPORT FOR HEPSERA International Nonproprietary Name: Adefovir Dipivoxil Procedure No. EMEA/H/C/485/II/3 7 Westferry

More information

V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.

V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M. COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,

More information

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses

More information

Natural History of HBV Infection

Natural History of HBV Infection Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2

More information

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir

More information

ACCEPTED. Title Page: Full Title: Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-Infected Patients with Mild. to Moderate Renal Impairment

ACCEPTED. Title Page: Full Title: Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-Infected Patients with Mild. to Moderate Renal Impairment JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print DOI: 10.1097/QAI.0000000000000476 Title Page: Full Title: Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-Infected

More information

STRIBILD (aka. The Quad Pill)

STRIBILD (aka. The Quad Pill) NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared

More information

SYNOPSIS Final Clinical Study Report for Study AI444031

SYNOPSIS Final Clinical Study Report for Study AI444031 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study

More information

Mutazioni di HBV in corso di trattamento; quale approccio razionale?

Mutazioni di HBV in corso di trattamento; quale approccio razionale? Mutazioni di HBV in corso di trattamento; quale approccio razionale? Prevenire Interpretare Trattare Marco Lagget UODU Gastroenterologia ed Epatologia AOU San Giovanni Battista di Torino Prevenire 1) Timing

More information

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Hepatitis B. Epidemiology and Natural History and Implications for Treatment Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco

More information

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline

More information

27/01/17. Post-partum ALT flare. HBV vaccine cannot protect all babies from high viral load carrier mothers

27/01/17. Post-partum ALT flare. HBV vaccine cannot protect all babies from high viral load carrier mothers Trepo, Chan and Lok. Lancet 2014;384:2053-63 Prevalence High (>7%) Intermediate (2%-7%) Low (

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information